Kronos Bio Company Leadership
| KRON Stock | USD 0.95 0.01 1.04% |
Kronos Bio employs about 58 people. The company is managed by 16 executives with a total tenure of roughly 136 years, averaging almost 8.0 years of service per executive, having 3.63 employees per reported executive. Analysis of Kronos Bio's management performance can provide insight into the firm performance.
Kronos Bio's Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2024-06-27 | Norbert W Bischofberger | Acquired 410848 @ 1.17 | View | ||
| 2024-06-12 | Norbert W Bischofberger | Acquired 881913 @ 1.24 | View | ||
| 2024-06-10 | Norbert W Bischofberger | Acquired 1378901 @ 0.88 | View | ||
| 2024-02-21 | Elizabeth A Olek | Disposed 7368 @ 1.05 | View | ||
| 2024-01-04 | Jorge Dimartino | Disposed 12009 @ 1.18 | View | ||
| 2023-12-12 | Jorge Dimartino | Disposed 17367 @ 1.3 | View |
Monitoring Kronos Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Kronos |
Kronos Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.2828) % which means that it has lost $0.2828 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.63) %, meaning that it created substantial loss on money invested by shareholders. Kronos Bio's management efficiency ratios could be used to measure how well Kronos Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.55. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Kronos Bio's Total Assets are very stable compared to the past year. As of the 30th of November 2024, Non Current Assets Total is likely to grow to about 42.7 M, while Net Tangible Assets are likely to drop about 225.4 M.As of the 30th of November 2024, Common Stock Shares Outstanding is likely to drop to about 55.8 M. In addition to that, Net Loss is likely to drop to about (125.9 M)
Kronos Bio Workforce Comparison
Kronos Bio is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 465. Kronos Bio retains roughly 58.0 in number of employees claiming about 12% of equities under Health Care industry.
Kronos Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kronos Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kronos Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kronos Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ridloff Elena 18 hours ago Acquisition by Ridloff Elena of 17000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | ||
Charles Lin over a month ago Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3 | ||
Frisbee Allison over two months ago Disposition of tradable shares by Frisbee Allison of Kronos Bio subject to Rule 16b-3 | ||
Tanen David M over two months ago Acquisition by Tanen David M of 34000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | ||
Yang Taiyin over three months ago Acquisition by Yang Taiyin of 17000 shares of Kronos Bio subject to Rule 16b-3 | ||
Norbert Bischofberger over three months ago Acquisition by Norbert Bischofberger of 204670 shares of Kronos Bio at 1.2457 subject to Rule 16b-3 | ||
Tanen David M over three months ago Acquisition by Tanen David M of 34000 shares of Kronos Bio at 0.95 subject to Rule 16b-3 | ||
Dimartino Jorge over three months ago Acquisition by Dimartino Jorge of 137008 shares of Kronos Bio subject to Rule 16b-3 |
Kronos Bio Notable Stakeholders
A Kronos Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kronos Bio often face trade-offs trying to please all of them. Kronos Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kronos Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Norbert Bischofberger | CEO President | Profile | |
| Deborah Knobelman | COO CFO | Profile | |
| David JD | Secretary Director | Profile | |
| Christopher Dinsmore | Strategic Advisor | Profile | |
| Stephanie Yao | Exec Communications | Profile | |
| Barbara JD | Strategic Advisor | Profile | |
| Marni Kottle | Sr Relations | Profile | |
| Rocio Hoyos | Senior Management | Profile | |
| Joshua Kazam | CoFounder Director | Profile | |
| Sandra Gardiner | Interim Officer | Profile | |
| MPH DO | Senior Development | Profile | |
| Allison JD | Senior Counsel | Profile | |
| Charles Lin | Senior Development | Profile | |
| BCh BM | CFO Devel | Profile | |
| Margaux Bennett | Vice Relations | Profile | |
| Wes Trotter | Senior Development | Profile |
About Kronos Bio Management Performance
The success or failure of an entity such as Kronos Bio often depends on how effective the management is. Kronos Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kronos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kronos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.71) | (0.67) |
Kronos Bio Workforce Analysis
Traditionally, organizations such as Kronos Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kronos Bio within its industry.Kronos Bio Manpower Efficiency
Return on Kronos Bio Manpower
| Revenue Per Employee | 108.4K | |
| Revenue Per Executive | 393K | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 7M | |
| Working Capital Per Employee | 2.7M | |
| Working Capital Per Executive | 9.6M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.